Integrated multidisciplinary model positions Hyderabad as a growing referral hub for advanced pediatric care
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Routine tests undertaken by women dropped by 35% in 2020
Subscribe To Our Newsletter & Stay Updated
